Actively Recruiting
Bone Marrow Microenvironment Signatures for Predicting AML Prognosis and Resistance
Led by Fujian Medical University Union Hospital · Updated on 2026-05-14
405
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on adult patients newly diagnosed with acute myeloid leukemia (AML) to study how factors in the bone marrow environment, such as IL-6, leptin, and fumarate, affect resistance to chemotherapy. The study aims to identify these factors as potential biomarkers for predicting treatment response and overall prognosis. It also plans to use patient-derived mouse models to better understand their roles in chemotherapy resistance. The study will enroll 405 AML patients following Chinese guidelines for diagnosis and treatment, along with 81 healthy controls matched by age and sex. Researchers will analyze bone marrow fluid samples to measure these factors and evaluate their connection to treatment outcomes after one cycle of chemotherapy. The mouse models derived from patient cells will help confirm the impact of these factors on chemoresistance. Participants will be monitored for treatment responses such as overall response rate within the first month and long-term outcomes including overall survival over three years. Data collection includes bone marrow sample analysis and clinical assessments. The study will track safety and prognosis to provide insight into potential new targets for AML therapies. Participation duration spans from diagnosis through follow-up periods up to three years.
CONDITIONS
Brief Title
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis aligns with the Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)
- Patients are experiencing their first onset of AML and have not received prior chemotherapy
- Patients participate with family support and sign informed consent
You will not qualify if you...
- Patients with other active malignancies requiring treatment
- Presence of infectious diseases including SARS, viral hepatitis, or HIV/AIDS
- Major surgery performed within the last 21 days
- Performance Status score greater than 3
- Severe liver or kidney dysfunction or serious infection
- Severe psychiatric conditions impairing understanding or voluntary withdrawal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed to collect biomarker data from bone marrow samples and clinical outcomes related to AML chemosensitivity.
Follow-up visits during the first month after chemotherapy and periodic assessments up to 3 years
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Actively Recruiting
Research Team
H
Huifang Huang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here